RP G28

Drug Profile

RP G28

Alternative Names: RP-G28

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator Ritter Pharmaceuticals
  • Developer Ritter Pharmaceuticals; University of British Columbia
  • Class Digestion aids; Oligosaccharides
  • Mechanism of Action Bacterial growth stimulants; Carbohydrate metabolism stimulants; Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Lactose intolerance
  • Preclinical Gastrointestinal disorders

Most Recent Events

  • 13 Feb 2017 Ritter Pharmaceuticals and University of British Columbia agree to develop RP G28 for Intestinal disorders
  • 13 Feb 2017 Preclinical trials in Gastrointestinal disorders in USA (PO)
  • 15 Aug 2016 Ritter Pharmaceuticals completes enrolment in its phase II/III trial for Lactose intolerance in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top